Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)# P-value Reference Clinical Outcome Invasive - Dead at 3 Years - Dead at5 years - Recurrence at 1 Year Invasive Lobular - Recurrence at 3 Years - Recurrence at 5 Years Invasive - Metastatic Event at 1 Alive(38) Dead(5) (1.192) 0.039 Alive(67) Dead(11) (1.167) 0.027 Alive(138) Dead(21) (1.389) 0.016 Pawitan, Y., et al., Alive(21) Dead(20) (1.59) 0.001 Esserman, L.J., et al., Alive(31) Dead(10) (1.194) 0.005 Alive(121) Dead(38) (1.45) 0.001 Pawitan, Y., et al., No(48) Yes(3) (-1.172) 0.002 Ma, X.J., et al., 2004 No(10) Yes(3) (3.122) 0.028 No(228) Yes(63) (1.019) 0.032 et al., 2002 No(16) Yes(31) (1.318) 0.021 Esserman, L.J., et al., No(5) Yes(3) (2.358) 0.016 No(9) Yes(3) (3.525) 0.021 No(195) Yes(91) (1.016) 0.037 et al., 2002 No(180) Yes(93) (1.386) 0.018 Wang, Y., et al., No(155) Yes(3) (-1.558) 3.58E-04 1
Tumor Grade Tumor Year - Metastatic Event at 3 Years - Metastatic Event at 5 Years - Grade - Advanced N No(238) Yes(52) (1.028) 0.009 et al.,2002 No(223) Yes(99) (-1.148) 1.75E-04 No(16) Yes(67) (1.287) 0.027 Kao, K.J., et al., No(206) Yes(78) (1.018) 0.029 et al., 2002 No(61) Yes(110) (-1.187) 2.88E-04 Grade 2 Grade Stickeler, E., et al., (2.128) 0.016 (15) 3 (16) Bloom-Ric Bloom-Ri hardson chardson Grade 1 Grade 2 (1.844) 0.003 Lu, X., et al., (5) (8) Grade 1 Grade 2 Expression Project (3.362) 0.022 (5) (3) for Oncology 0.524 0.04 (3) (6) 3 (3) Grade 1 Grade 2 (1.091) 0.03 (40) (26) 0.151 0.044 (13) (81) 3 (34) Finak, G., et al., 0.229 0.049 (3) (23) 3 (27) Grade 2 Grade Julka, P.K., et al., (-1.581) 0.008 (22) 3 (4) Kreike, B., et al., -0.313 0.016 (10) (11) 3 (26) N0 (179) N1+ (205) (1.15) 1.18E-05 TCGA N0 N1+ (12) (1.215) 0.005 TCGA N0 (65) N1+ (32) (1.393) 0.007 Symmans, W.F., et al., 2010 N0 (110) N1+ (80) (1.095) 0.013 Symmans, W.F., et al., 2010 N0 (41) N1+ (36) (1.131) 0.025 Loi, S., et al., N0 (4) N1+ (11) (1.474) 0.049 Lu, X., et al., N0 (29) N1+ (58) (-1.162) 0.01 Loi, S., et al., N0 (3) N1+ (8) (-1.077) 0.048 Ma, X.J., et al., 2009 I II 0.169 8.24E-04 TCGA 2
(46) (207) III (78) IV (12) - Advanced II III (10) (1.161) 0.033 TCGA II III (10) (-1.637) 0.038 TCGA 0 (29) I (29) II (43) III (9) -0.179 0.03 0 (425) I II (446) III (69) IV (8) -0.062 0.015 (257) (87) (228) (2.887) 1.56E-14 TCGA (42) (57) (1.708) 0.002 Minn, A.J., et al., (382) (1,156) (1.064) 1.17E-06 Estrogen Receptor (ER) (21) (205) (43) (297) (75) (1.243) 0.008 Ginestier, C., et al., (1.118) 1.20E-05 (1.132) 0.008 Chin, K., et al., (60) (45) (1.107) 0.036 Saal, L.H., et al., Molecular biomarker s (56) (123) (102) (204) (1.302) 0.037 (1.16) 0.004 Kao, K.J., et al., (128) (191) (2.27) 5.10E-11 TCGA (35) (25) (1.134) 0.018 Korde, L.A., et al., 2010 Progestero (55) (43) (1.679) 0.001 Minn, A.J., et al., ne Receptor(P (20) (1.261) 0.046 Julka, P.K., et al., R) (5) (9) (1.166) 0.035 (27) (1.152) 0.038 (26) (1.2) 0.024 Ginestier, C., et al., 3
(258) (243) (1.058) 0.019 (6) (25) (-1.228) 0.025 TCGA (21) (64) (-1.216) 0.019 Loi, S., et al., (18) (59) (-1.15) 0.046 Loi, S., et al., (4) (3) (1.654) 0.006 Schuetz, C.S., et al., ERBB2 (33) (4) (1.236) 0.004 Boersma, B.J., et al., (195) (68) (1.154) 7.18E-04 TCGA (8) (3.582) 2.24E-05 Stickeler, E., et al., (-3.354) 1.93E-12 TCGA (253) (46) (-1.095) 3.31E-04 (320) (178) R/ PR (87) (-1.148) 0.02 Chin, K., et al., (-1.098) -1.098 (1,340) (211) (74) (-1.196) 0.049 Esserman, L.J., et al., (-1.265) 0.012 Kao, K.J., et al., (295) (32) (-1.08) 0.042 Bonnefoi, H., et al., 4
(32) (80) *All studies with a p value < 0.05 in t-test are shown. # and represent an increased and decreased expression in class 2 compared with class 1, respectively. Numbers in parentheses represent fold changes. References The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature,. 486(7403): p. 346-52. Pawitan, Y., et al., Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Cancer Res,. 7(6): p. R953-64. Esserman, L.J., et al., Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Cancer Res Treat,. 132(3): p. 1049-62. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res,. 13(11): p. 3207-14. et al., A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med, 2002. 347(25): p. 1999-2009. Ma, X.J., et al., A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 2004. 5(6): p. 607-16. Wang, Y., et al., Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet,. 365(9460): p. 671-9. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA,. 305(18): p. 1873-81. Kao, K.J., et al., Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer,. 11: p. 143. Stickeler, E., et al., Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer. Oncol Rep,. 26(4): p. 1037-45. Lu, X., et al., Predicting features of breast cancer with gene expression patterns. Cancer Res Treat,. 108(2): p. 191-201. Finak, G., et al., Stromal gene expression predicts clinical outcome in breast cancer. Nat Med,. 14(5): p. 518-27. Julka, P.K., et al., A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br J Cancer,. 98(8): p. 1327-35. 5
Kreike, B., et al., Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res,. 12: p. 5705-12. Symmans, W.F., et al., Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol, 2010. 28(27): p. 4111-9. Loi, S., et al., Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics,. 9: p. 239. Loi, S., et al., Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol,. 25(10): p. 1239-46. Ma, X.J., et al., Gene expression profiling of the tumor microenvironment during breast cancer progression. Cancer Res, 2009. 11(1): p. R7. Minn, A.J., et al., Genes that mediate breast cancer metastasis to lung. Nature,. 436(7050): p. 518-24. Ginestier, C., et al., Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res,. 12(15): p. 4533-44. Chin, K., et al., Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell,. 10(6): p. 529-41. Saal, L.H., et al., Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A,. 104(18): p. 7564-9. Korde, L.A., et al., Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Cancer Res Treat, 2010. 119(3): p. 685-99. Schuetz, C.S., et al., Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res,. 66(10): p. 5278-86. Boersma, B.J., et al., A stromal gene signature associated with inflammatory breast cancer. Int J Cancer,. 122(6): p. 1324-32. Bonnefoi, H., et al., Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol,. 8(12): p. 1071-8. 6